Will CVC Break Its Silence on PharmaResearch Split—Must Asset Management Sets Response Deadline D-1

CVC Capital Partners faces mounting pressure to clarify its stance on PharmaResearch’s spin-off, as Must Asset Management demands answers over governance and succession concerns, with key conversion and redemption rights at stake.